STOCKS TELEGRAPH

Category: Mid Day Movers

  • On What Basis Did Hut 8 Stock Rises 17% Today?

    Hut 8 Mining Corp. (HUT) has gained 17.85% to $4.92 in the current market price on Monday. HUT stock ended the prior trading session at $4.09. HUT 8 traded in the range of $4.00 to $4.29 in the current session. Hut stock exchanged 2.93 million shares so far in the current session, a volume that exceeded its average daily trading volume of 1.46 million shares for the last 100 days.

    HUT shares have gained 3.81% over the last five days and 13.10% over the past month. Since HUT stock rose in the absence of any current information, there may be some reason to believe recent developments could provide additional insight regarding it.

    How has Hut 8 been recently?

    Hut 8 is a North American company with a unique focus on innovation and decentralized systems, integrating them into its mining operation. With one of the highest installed capacity rates in the business and more self-mined Bitcoin than any publicly traded company or crypto miner worldwide, HUT is located in energy-rich Alberta, Canada.

    In addition to profitable digital asset mining, HUT offers high-performance computing services and yield & income programs based on its Bitcoin reserves. HUT is helping define the digital asset revolution with innovation, imagination, and passion to create value and benefits for its shareholders and subsequent generations.

    A mutual agreement between Hut 8 Mining and Bitfury BV has terminated the historical Investor Rights Agreement (“IRA”) between the two companies.

    • HUT has been in partnership with Bitfury for a number of years and has enabled it to advance bitcoin mining in Canada.
    • The termination of the IRA will result in Bitfury losing its right to nominate a board member to Hut 8.
    • For the sake of working through the transition, Hut 8 has allowing Jeremy Sewell’s resignation to be delayed until January 1, 2021 to allow the Hut 8 Board time to transition.
    • Late last month, Hut 8 purchased 11,090 MicroBT M30S, M30S+, and M31S miners from SuperAcme Technology (Hong Kong) Limited (“SuperAcme”) for $44.373 million USD, or $44/terahash.
    • Delivery of the miners will begin in October 2021, with HUT expecting the full deployment in December 2021.
    • In addition to this purchase, earlier in the prior week HUT purchased 863 M30S+ and M30S units that will be delivered and deployed by July 2021.

    How will these purchases increase HUT’s capacity?

    As a result of both purchases, Hut 8’s installed capacity should increase by approximately 2.5 E/H, which is in addition to previously announced investments. In partnership with Validus Power, the new fleet of miners will comprise the first operational fleet for the 100 MW facility that the HUT plans to build.

  • Gaotu Techedu Inc. (GOTU) Stock Plummets Following Rising Oversight and Involvement by Chinese Government in Private Education Sector

    Gaotu Techedu Inc. (GOTU) stock prices plummeted by 24.72% some time after market trading commenced on July 26th, 2021, bringing the price per share down to USD$2.65 early on in the trading day.

    New Regulations

    China recently announced a massive set of new regulations for private education companies, primarily aimed at decreasing workloads for students. The government mandates were also designed to overhaul a marketspace that it claims has been “hijacked by capital”. The regulations ban companies such as GOTU stock that adhere to school curriculums from generating profits, raising capital, or going public. School-related tutoring can no longer be offered on weekends or during vacations. They also cannot give classes to children under the age of six, a demographic that has been increasingly pushed to start studying from an earlier age.

    GOTU Stock in Changed Landscape

    The Chinese education technology sector reached a value of USD$100 billion as companies like GOTU stock catered to the increasing number of parents wanting to give their children an early academic advantage. The regulation changes will see business models being drastically altered as companies are forced into making extensive changes in order to maintain compliance. The drastic change will see the prohibition of the overseas investments that have been the lifeblood of the sector. Companies that find themselves in violation of the new regulations are required to rectify the situation, as appropriate.

    Details of Regulations

    The private education sector attracted billions of dollars and was expected to generate USD$76 billion in revenue by 2024, of which GOTU stock hoped to be a part. The regulatory branch that aims to regulate the industry was formed in June 2021 and aims to devise and oversee the changes. The regulations were expressed in general terms, with broad applicability to common practices throughout the industry. The regulations are directed at compulsory subjects, with supplementary subjects such as art and music avoiding falling under the umbrella of the new regulations.

    Government Involvement

    The regulations were jointly announced on July 24th, 2021 by the General Office of the Communist Party of China Central Committee and the General Office of the State Council. The set of rulings aims to mitigate the excess associated with homework and after-school tutoring for students as young as six who are receiving mandatory education.

    Future Outlook for GOTU Stock

    As one of the many up and coming companies that is forced to make adjustments to adhere to the new regulations, GOTU stock is keen to capitalize on the education sector being disrupted. Current and potential investors are hopeful that management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Is There Any Reason Why The SPX FLOW Stock Is Expanding Today?

    As of the last check, shares of the leading provider of process solutions SPX FLOW Inc. (FLOW) were rising 10.06% to $83.78. Friday session ended with FLOW stock at $76.12. On the day, SPX FLOW traded 0.32 million shares, which was higher than the average daily volume of 0.17 million shares over the past 50 days.

    Since the beginning of the year, FLOW shares have increased by 93.59%, and they have gained by 22.60% over the last week. FLOW stock price has gained 11.96% over the past three months, and 38.07% over the past six months. The market value of FLOW is $3.22 billion, and the number of outstanding shares is 42.00 million. News of the company exploring strategic alternatives is driving up FLOW stock.

    What are the alternatives that FLOW Stock is considering?

    SPX FLOW is a Charlotte, N.C.-based company providing innovative solutions to the world. Flow’s product portfolio is focused on technologies for mixing, blending, fluid handling, separation, thermal heat transfer, and other operations vital to processes undertaken by organizations across a wide spectrum of markets, including nutrition, health, and precision manufacturing. SPX FLOW stock has sales and operations in more than 140 countries and has approximately $1.4 billion in 2020 revenue.

    A review of strategic alternatives was authorized today by SPX FLOW’s Board of Directors.

    • Alternatively, FLOW may be sold or merged, or its standalone strategy may continue to be employed.
    • A proposal from Ingersoll Rand Inc. to purchase all outstanding shares of SPX FLOW common stock for $85.00 per share had been received and rejected by FLOW’s Board of Directors.
    • Ingersoll Rand had previously proposed $81.50 per share in an unsolicited proposal.
    • In consultation with its legal and financial advisors, and at the recommendation of an independent director committee for evaluation of the potential transaction, the FLOW stock Board concluded that the proposals did not adequately value the company in light of the potential for increased profits related to executing the company’s strategic plan.
    • With the attention of additional interested parties, the board of FLOW believes the time is right to pursue a range of strategic alternatives aimed at bringing value to its shareholders.
    • The Morgan Stanley is SPX FLOW’s financial advisor and Winston & Strawn LLP serves as its legal advisor.
    • In collaboration with external advisors, FLOW plans to engage with various parties and share additional information regarding its plans for growth, subject to compliance with confidentiality and other security protocols.

    FLOW’s further comments on the alternative strategy:

    FLOW did not provide any timetable of the review process and said that the outcome cannot be guaranteed at this point. No further comments, including those made publicly, regarding this review will be made until the review is complete or until SPX FLOW determines that disclosure is necessary.

  • Why Tyme Technologies, Inc. (TYME) stock is moving high today?

    Tyme Technologies, Inc. (TYME) stock announced the receival of notification from the United States Patent and Trademark Office that states the grant of additional patent claims regarding Tyme’s metabolomic technology platform. The TYME stock price saw a push of 38.89% to reach $1.50 a share as of this writing. The stock was gloomy at the previous trading session and went down by 2.70%. Let’s deep dive to explore more of it.

    What’s Happening?

    Tyme Technologies, Inc is the biotechnology stock focused on the development of therapeutics related to cancer metabolism in the United States of America. The U.S patent no 11,058,638 which the TYME stock has been granted is related to the delivery of therapeutics to the targeted cancer cells.

    TYME stock Technology:

    The technology of the Tyme Technologies works in such a manner that the tyrosine isomer racemetyrosine fuses a second therapeutic agent in order to create a fusion compound that allows the targeted delivery to cancer cells in a novel manner. This delivery method affirms the metabolic phenomenon in which the cancer cells grow by consuming a high quantity of non-essential amino acids, in which tyrosine is also included. These cancer cells get non-essential amino acids from their surrounding as they themselves cannot make enough of these i.e., amino acids.

    This delivery technology requires further studies which TYME stock is planning to start this year. As it is the investigational procedure of drug delivery in the pre-clinical phase, it is not approved by the U.S for any disease indication.

    TYME stock’s Chief Scientific Officer Remarks:

    The Chief Scientific Officer of the TYME stock considered the delivery technology as the opportunity for Tyme Technologies for the expansion of TYME’s current cancer-metabolism-based approach with a drug delivery platform. He emphasized that this technology would help in the improvement of safety and efficacy of the wide range of anticancer drugs.

    Conclusion:

    Investors are responding to the recent news related to the U.S patent which TYME stock did announce today. The stock is bullish today and the trading volume is well above the average. The delivery technology of TYME is in the early stages but it can leverage itself in the future.

  • Here’s why IAMGOLD Corporation (IAG) stock’s share-price plunged

    There was a decline in the share price of IAMGOLD Corporation (IAG) by -9.79% and were trading at a stock price of $2.54. IAG’s stock volume stayed the same at 4.97 million shares, however, this was higher than the average volume of the past 50 days which was 3.96 million shares. Over the last 12 months, there has been a decline in shares of IAG by -41.09%, and the last week they have decreased by -4.42%. IAG’s stock has declined by -18.79% over the last three months and in the last six months, the stock’s value has decreased by -19.48%. The outstanding shares of IAMGOLD stand at 475.80 million and their current market value is $1.42 billion.

    IAMGOLD Corporation at a glance

    IAMGOLD Corporation, headquartered in Toronto, Canada, is a developer, operator, and explorer for gold mining properties in three regions: Western Africa, North and South America. IAMGOLD is developing high potential mining districts that help them in developing, operating, and exploring projects. Its operational mines comprise of the Westwood mine (Quebec, Canada), the Essakane mine (Burkina Faso, West Africa), and the Rosebel mine (Suriname, South America). Some of its development and exploratory projects are the Diakha-Siribaya gold project (Mali), the Cote gold project (Ontario) and the Boto gold project (Senegal), and various other countries located in America and Western Africa. IAMGOLD is estimated to employ 5,000 people and commits itself to maintain the culture of accountable mining by following high social and environmental standard practices.

    IAMGOLD reports second Quarter financial results for 2021

    The Essakane mine had produced strong and promising results of the second quarter with high gold production in spite of the fact that there were numerous challenges in ore processing with high graphitic content. The production guidance has been increased for the Essakane project which will reflect higher production in the first two quarters of 2021.
    On the other hand, the Westwood mine required additional safety measures because of which the production guidance for Westwood 2021 had to be reduced to reflect this.
    Due to difficult operating conditions, mining activities in the Rosebel mine were impacted in the second quarter, which was caused by heavy rainfall. In addition to the operating conditions, there was also a significant increase in COVID-19 cases as there had emerged a new variant in Suriname during the second quarter. The social impact of this greatly affected the projects and operations. The Guidance for Rosebel were adjusted downwards due to the said reasons.

    The company has summarized the results preliminary for second-quarter operations and also updated the 2021 guidance set on certain metrics. The changes in guidance have been made based on the first-half performance of 2021 and successive efforts for developing an updated outlook for the latter half of 2021.
    The full-year assumptions for the updated full-year guidance 2021 included the $65 average crude oil price per barrel and average realized gold price of $1,745 per ounce with a EUR: USD exchange rate of 1.2 and USD: CAD exchange rate of 1.22.
    The production guidance for the overall company has been reduced mainly due to the reduced actual production in Rosebel and Westwood mines, which was somewhat counterbalanced by high actual production in Essakane mine for the first half of 2021. Total per-ounce costs guidance had been increased which reflected lower total company-wide attributable guidance. The company, in accordance with IFRS, is trying to determine any kind of impairment for the Westwood mine and that it need adjustment or not.

  • Arvinas, Inc. (ARVN) Stock on the Rise Following Global Partnership with Pfizer

    Arvinas, Inc. (ARVN) stock prices were up by 8.68% some time after market trading commenced on July 22nd, 2021, bringing the price per share up to USD$84.28 early on in the trading day.

    Partnership with Pfizer

    July 22nd, 2021 saw the company announce its global collaboration with Pfizer in order to develop and commercialize ARV-471, an investigational oral PROTAC, estrogen receptor protein degrader. The estrogen receptor has been shown to drive diseases in most cases and forms of breast cancer. The treatment is currently in Phase 2 dose expansion clinical trial, designed to treat patients with estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-).

    Details of the Agreement

    As per the agreement, the partnering company will make an upfront payment of USD$650 million to ARVN, as well as a USD$350 million equity investment in the company. Global development costs, commercialization expenses, and profits will be split equally between the partnering companies. The combination of the company’s leadership in targeted protein degradation with Pfizer’s global capabilities and extensive expertise in breast cancer is expected to prove transformational.

    Scope of ARV-471

    This, in turn, will substantially enhance and accelerate the development and eventual commercialization of ARV-471 while concurrently advancing the company’s strategy of building a global and integrated biopharmaceutical company. Despite the advancement of the oncology space over recent years, there is still a sizeable unmet need that persists in the treatment of HR+ breast cancer. The partnership with Pfizer will see the deployment of PROTAC technology in a bid to help mitigate the devastation caused by the disease.

    ARV-471’s Potential

    December 2020 saw the company present interim data for its Phase 1 dose-escalation clinical trial of ARV-471 in patients with locally advanced or metastatic ER+/HER2- breast cancer. The treatment is indicated for its potential as a novel oral ER targeted therapy. Patients enrolled in the study were heavily pretreated, having been administered with cyclin-dependent kinase (CDK) 4/6 inhibitors. Despite the extensive pretreatment and the advanced stage of disease, the interim results demonstrated the treatment’s ability to promote substantial ER degradation and exhibits an encouraging clinical efficacy and tolerability profile.

    Future Outlook for ARVN Stock

    Armed with a massively expansive collaboration with Pfizer, the company is keen to make the most of the opportunities afforded to it as it expands and consolidates its market footprint. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to usher in organic growth over the long term.

  • NeuroMetrix, Inc. (NURO) Stock Soars Following Breakthrough Designation for Quell Device

    NeuroMetrix, Inc. (NURO) Stock Soars Following Breakthrough Designation for Quell Device

    NeuroMetrix, Inc. (NURO) stock prices skyrocketed by 145.51% some time after market trading commenced on July 20th, 2021, bringing the price per share up to USD$8.00 early on in the trading day.

    Breakthrough Designation Granted

    July 20th, 2021 saw the company announce that the United States Food and Drug Administration granted Breakthrough Designation for NURO’s Quell device, which is designed to treat symptoms of fibromyalgia in adults. With the company reporting moving forward with regulatory filing, it hopes to launch Quell for fibromyalgia indication by the second half of 2021.

    Fibromyalgia

    Fibromyalgia is a form of chronic pain that is associated with fatigue, sleep, cognitive, and mood disturbances. With nearly 2 to 6% of the population of the U.S being affected, diagnoses are most often made between the ages of 30 and 50. While the cause of the illness is unclear, studies have indicated abnormalities in the way the brain processes normal sensations and pain. Despite the FDA having approved several drugs for the management of fibromyalgia pain, there is still a significant unmet need for safe and effective non-pharmacological treatments.

    Quell Technology

    Quell is an innovative, non-invasive, nerve stimulation device that is designed to mitigate the effects of fibromyalgia. Covered by 18 U.S utility patents, it sets itself apart as the only wearable neurostimulator that functions with the use of a custom designed microchip. The device provides flexible, accurate, high-power nerve stimulation in a form factor not bigger than a credit card. The device uses position and motion sensing to automatically adjust stimulation output for an optimal patient experience over the course of the entire day. Bluetooth low energy is supported by the device in communication with its app, which is available on both Android and Apple mobile devices.

    Breakthrough Device Designation

    The FDA Breakthrough Device Program is designed to facilitate the accessibility of breakthrough technologies for the patients that need them urgently. As per the program, the FDA will provide a priority review for NeuroMetrix, as well as interactive communication regarding its development. Furthermore, government policies and programs currently in the works have the potential to facilitate Medicare reimbursement for FDA Breakthrough Devices after they have been granted marketing authorization.

    Future Outlook for NURO

    Armed with the support of the FDA, NURO is poised to capitalize on the massive market space it finds at its disposal. Current and potential investors are hopeful for the accelerated development and commercialization of Quell so as to maximize gains in shareholder value.

  • LSB Industries, Inc. (LXU) Stock Soars Following Exchange Agreement with LSB Funding LLC

    LSB Industries, Inc. (LXU) Stock Soars Following Exchange Agreement with LSB Funding LLC

    LSB Industries, Inc. (LXU) stock prices were up a massive 31.98% some time after market trading commenced on July 20th, 2021, bringing the price per share up to USD$6.48 early on in the trading day.

    Agreement with LSB Funding

    July 20th, 2021 saw the company announce the signing of a definitive agreement with LSB Funding LLC, an affiliate of Eldridge. The agreement will see shares of LSB Series E-1 and Series F-1 being exchanged for shares of LXU common stock. As per the agreement, the closing of the transaction will see LXU exchange roughly USD$300 million worth of preferred stock that is held by Eldridge into the equivalent value of LXU common stock. The exchange has been priced at USD$6.16 per share, which is equal to the 30-day volume-weighted average price as of the date of the agreement. Furthermore, LXU shareholders as of the record date will be granted a special dividend in the form of 0.30 shares of LXU for each share owned.

    Advancing the Partnership

    The closing of the transaction will result in the elimination of the company’s current financial impact and repayment of accrued compounding preferred stock and future accruing dividends at 14.5%. This number is set to increase to 16% in April 2023, with the move continuing to unburden the company, thereby unlocking shareholder value

    LXU’s Expanded Scope

    The Special Committee, Board of Directors, and company management are confident that the transaction has the potential to lead to an upgrade in its rating, thereby allowing LXU to refinance its senior secures notes at a lower interest rate and on improved terms. This, in turn, will facilitate a reduction of the cash interest expense and overall cost of capital for the company.

    Benefits of the Collaboration

    The transaction also serves to improve the company’s financial flexibility, allowing it to allocate resources towards organic growth initiatives, including, but not limited to, growth in green ammonia and clean energy and accretive M&A opportunities. Furthermore, the company will see its substantial tax attributes be preserved, including roughly USD$620 million of federal net operating losses. This facilitates the protection of prospective significant future cash savings and shareholder value.

    Future Outlook for LXU

    Armed with a highly promising collaboration, the company is poised to capitalize on the massively expanded scope of business it finds at its disposal. Current and potential investors are hopeful that management will be able to leverage their resources to facilitate a continued trajectory of success and growth in equity value.

  • Immunome, Inc. (IMNM) Stock Skyrockets Following Promising Results of IMM-BCP-01 in Neutralizing Delta Variant of Covid-19

    Immunome, Inc. (IMNM) Stock Skyrockets Following Promising Results of IMM-BCP-01 in Neutralizing Delta Variant of Covid-19

    Immunome, Inc. (IMNM) stock prices soared by 20.85% shortly after market trading commenced on July 20th, 2021, bringing the price per share up to USD$20.11 early on in the trading day.

    IMM-BCP-01

    July 20th, 2021 saw the company announced the potent neutralizing activity demonstrated by its three-antibody cocktail (IMM-BCP-01) against the Delta variant of the coronavirus pandemic. The treatment also showed in-vitro activity via non-neutralizing mechanics, such as complement fixation, which the company anticipates enabling viral clearance for the treatment.

    Addressing Delta Variant Concerns

    With the highly concerning evolution of the Covid-19 virus taking the world by storm, the company is hopeful that its drug candidate is adequately positioned to become a leader in the global fight against the deadly coronavirus. The treatment’s ability to maintain neutralizing activity against the newer Covid-19 variants is highly promising, with its mechanisms of action targeting at least three non-overlapping epitopes. The mechanisms are informed by an authentic human immune response and provide a robust defense against future mutational drift.

    Expediting Development

    With the majority of the current cases in the United States reporting infection with the Delta variant of the coronavirus, the company was awarded USD$17.6 million as a technology award to aid the development of the treatment. Granted by the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense in collaboration with the Defense Health Agency, the award serves to accelerate the availability of the treatment as the world hurtles towards universal immunizations.

    Ahead of the Curve

    With cases finally dwindling down, the United States is on high alert for the near-term potential for a resurgence of coronavirus infections, as a result of the emerging variants. The company is exploring all options to expedite the development of IMM-BCP-01, with plans to submit an IND application with the U.S Food and Drug Administration as early as this quarter. The biopharmaceutical company leverages its proprietary human memory B cell platform in a bit to aid the discovery and development of first-in-class antibody therapeutics.

    Future Outlook for IMNM

    Armed with a promising drug candidate that could address the massive gap that arose in the marketspace as a result of the proliferation of the Delta variant, IMNM is poised to capitalize on the expanded scope of the opportunities afforded to it. Investors are hopeful that management will be able to spearhead the commercialization and proliferation of IMM-BCP-01, thus resulting in increases in shareholder value over the long term.

  • Infobird Co., Ltd. (IFBD) Stock Surges Following Successful Launch of Intelligent SaaS Solution for Leading Client

    Infobird Co., Ltd. (IFBD) Stock Surges Following Successful Launch of Intelligent SaaS Solution for Leading Client

    Infobird Co., Ltd. (IFBD) stock prices were up by 8.49% shortly after market trading commenced on July 20th 2021, bringing the price per share up to USD$3.45 early on in the trading day.

    IFBD’s SaaS Product

    July 20th 2021 saw the company announce the successful implementation of its proprietary Intelligent Quality Inspection SaaS with a leading Chinese Fintech company. The SaaS product has facilitated the realization of intelligent management and operation by IFBD’s client’s customer service platform. The Intelligent Quality Inspection SaaS also serves as the basis for further upgrading of the client’s customer service.

    Intelligent Quality Inspection

    The company has persisted in promoting the implementation of intelligent quality inspection across a myriad of market sectors over the past few years, serving to facilitate the expansion of the scope of application of intelligent quality inspection. Since its inception, Intelligent Quality Inspection has catered to financial, e-commerce, retail, and other industries. The standardized intelligent SaaS product will give clients the ability to better track the engagement between the company and its end customers.

    Scope of IFBD’s Solution

    With a range of applicability in so many sectors, the solution is essential for the financial industry on account of its very high compliance and service requirements for customer and sales centers. The company’s success in serving its Fintech client with Intelligent Quality Inspection will serve as the track record that will bolster IFBD’s foray into the financial industry.

    Advantages of IQI

    The partnering Fintech company prioritizes customer service, while constantly seeking to elevate the quality of management and customer service it offers. This is facilitated by various methods, including, but not limited to, quality inspection and training. The adoption of the Intelligent Quality Inspection system has seen the advancement from manual inspections by random sampling to automatic inspection with 100% coverage. This results in the obsolescence of quality inspectors with the achievement of 100% inspections serving to comprehensively improve management efficiency. With such complete coverage, the company negates the risk of product or service defects slipping through the cracks of selective, random inspections.

    Future Outlook for IFBD

    Armed with the successful implementation of its leading SaaS product, IFBD is poised to capitalize on the expanded scope of opportunities it finds at its disposal as a result of its partnership. Investors are hopeful that the success of this collaboration will pave the way for the company to expand its network of clients, ushering in significant and sustained increases in shareholder value over the long term.